<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">OPP</journal-id>
<journal-id journal-id-type="hwp">spopp</journal-id>
<journal-id journal-id-type="nlm-ta">J Oncol Pharm Pract</journal-id>
<journal-title>Journal of Oncology Pharmacy Practice</journal-title>
<issn pub-type="ppub">1078-1552</issn>
<issn pub-type="epub">1477-092X</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1078155211436023</article-id>
<article-id pub-id-type="publisher-id">10.1177_1078155211436023</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Case Reports</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Fluorodeoxyglucose-induced allergic reaction: A case report</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Codreanu</surname><given-names>Ion</given-names></name>
<xref ref-type="corresp" rid="corresp1-1078155211436023"/>
</contrib>
<aff id="aff1-1078155211436023">Department of Radiology, The University of Arizona Medical Center, Tucson, AZ, USA</aff>
</contrib-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Dasanu</surname><given-names>Constantin A</given-names></name>
</contrib>
<aff id="aff2-1078155211436023">Department of Hematology-Oncology, St. Francis Hospital and Medical Center, Hartford, CT, USA</aff>
</contrib-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Weinstein</surname><given-names>Gregory S</given-names></name>
</contrib>
<aff id="aff3-1078155211436023">Department of Otorhinolaryngology, Head and Neck Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA, USA</aff>
</contrib-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Divgi</surname><given-names>Chaitanya</given-names></name>
</contrib>
<aff id="aff4-1078155211436023">Department of Radiology, Columbia University Medical Center, New York, NY, USA</aff>
</contrib-group>
<author-notes>
<corresp id="corresp1-1078155211436023">Ion Codreanu, Department of Radiology, The University of Arizona Medical Center, 1501 North Campbell Ave. P.O. Box 245067, Tucson, AZ 85724, USA. Email: <email>codrion@yahoo.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>3</month>
<year>2013</year>
</pub-date>
<volume>19</volume>
<issue>1</issue>
<fpage>86</fpage>
<lpage>88</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>The number of diagnostic positron emission tomography/computed tomography (PET/CT) procedures performed in the USA and worldwide is rapidly increasing. Although the benefits of these procedures are obvious, the increasing use of radiopharmaceuticals requires a better understanding of potential adverse affects and their proper management. We present herein the first report of an allergic reaction to fluorodeoxyglucose in the setting of repeated PET/CT scans for restaging purposes in a patient with pyriform sinus cancer.</p>
</abstract>
<kwd-group>
<kwd>Allergy</kwd>
<kwd>F18-FDG</kwd>
<kwd>PET radiopharmaceutical</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-1078155211436023" sec-type="intro"><title>Introduction</title>
<p>Fluoride, the ionic form of fluorine, represents the 13th most abundant element in the crust of the earth. Fluorine’s highest electronegativity makes it one of the most chemically reactive elements, giving unique properties to many of its compounds. Organic fluorine compounds are widely used in medicine. Despite the remarkable impact of fluorinated molecules in clinical medicine, they are not completely devoid of risk. Contact dermatitis and acne-like eruptions have been associated with fluorinated toothpaste.<sup><xref ref-type="bibr" rid="bibr1-1078155211436023">1</xref>,<xref ref-type="bibr" rid="bibr2-1078155211436023">2</xref></sup> Occupational contact dermatitis and allergies to fluorinated anesthetics have been described in anesthesiology staff.<sup><xref ref-type="bibr" rid="bibr3-1078155211436023">3</xref>,<xref ref-type="bibr" rid="bibr4-1078155211436023">4</xref></sup> Occasional reports of hypersensitivity reactions have been reported with many other fluorinated agents such as quinolones,<sup><xref ref-type="bibr" rid="bibr5-1078155211436023">5</xref>,<xref ref-type="bibr" rid="bibr6-1078155211436023">6</xref></sup> antifungals,<sup><xref ref-type="bibr" rid="bibr7-1078155211436023">7</xref><xref ref-type="bibr" rid="bibr8-1078155211436023"/><xref ref-type="bibr" rid="bibr9-1078155211436023"/>–<xref ref-type="bibr" rid="bibr10-1078155211436023">10</xref></sup> selective serotonin reuptake inhibitors,<sup><xref ref-type="bibr" rid="bibr11-1078155211436023">11</xref></sup> and even fluorinated corticosteroids.<sup><xref ref-type="bibr" rid="bibr12-1078155211436023">12</xref><xref ref-type="bibr" rid="bibr13-1078155211436023"/>–<xref ref-type="bibr" rid="bibr14-1078155211436023">14</xref></sup> We report an allergic reaction to fluorine-18-labeled fluorodeoxyglucose (F18-FDG), the most common radiopharmaceutical used in positron emission tomography. To the best of our knowledge, there are no previous reports of allergic reactions to F18-FDG in the world literature.</p>
</sec>
<sec id="sec2-1078155211436023" sec-type="cases"><title>Case report</title>
<p>We describe a 59-year-old male with history of squamous cell carcinoma of the right pyriform sinus (T1N2aM0), status post-transoral robotic surgery, supracricoid right hemipharyngolaryngectomy and neck dissection, followed by chemoradiotherapy. The patient reported having recurring body rash and itching after two of his restaging positron emission tomography/computed tomography (PET/CT) scans done 3.5 months apart. Each PET/CT scan was performed 60 min after injection of <italic>circa</italic> 15.0 mCi of F18-FDG. No oral contrast or other medications were administered during the scan visits. The prominence of the body rash and itching for over 24 h prompted a visit to a dermatologist who prescribed fexofenadine, with some symptom relief.</p>
<p>The patient had known allergies to bupropion (hives), penicillins (rash, fever), trimethoprim–sulfamethoxazole (diarrhea, dry heaves, stomach cramps) and clindamycin (rash). Notwithstanding, none of these medications were taken in that period. Past medical history was significant for hypertension, hyperlipidemia, and hypothyroidism. At baseline, he complained of chronic dry mouth, mild taste disturbance, and difficulty swallowing, which developed as a result of chemoradiation and remained stable over time. The medications he was taking included aspirin 81 mg orally daily and <sc>l</sc>-thyroxine 175 mcg orally daily.</p>
<p>Skin examination revealed the presence of pruritic, red papules on the face, trunk, and extremities. A few scratch marks were present in his back. Physical examination was otherwise unremarkable.</p>
<p>Laboratory studies performed several days after the scan showed the following: hemoglobin 14.8 g/dL, hematocrit 42%, white blood cell count 3.9 × 10<sup>3 </sup>µL<sup>−1</sup>, neutrophils 72%, lymphocytes 11%, monocytes 10%, eosinophils 6%, basophils 1%, and platelets 259 × 10<sup>3 </sup>µL<sup>−1</sup>. His baseline eosinophils during previous year varied between 0% and 3%.</p>
<p>The PET/CT scans showed post-surgical changes in the larynx and right neck, with no abnormal foci of increased radiotracer uptake to suggest residual or metastatic disease.</p>
<p>As a premedication before future PET/CT scans, the patient was prescribed prednisone 50 mg (one tablet 12 h prior to scan and one tablet 2 h prior to scan) and 25 mg diphenhydramine (one tablet 10 h prior to scan). This proved to be effective and no allergic symptoms were reported during a subsequent PET/CT scan.</p>
</sec>
<sec id="sec3-1078155211436023" sec-type="discussion"><title>Discussion</title>
<p>F-18 FDG PET scan is a relatively new, but expanding imaging modality. With increasing number of individuals exposed to F18-FDG, the number of allergic reactions is expected to increase. To date, there are no published reports of allergic reactions to F18-FDG and, to our knowledge, this represents the first such case.</p>
<p>Chemically, F18-FDG represents a glucose molecule with an attached positron emitting radioactive isotope fluorine-18 in the 2′ position. Given a variety of allergic reactions reported to fluorinated molecules, we hypothesize that allergic reactions to F18-FDG can also be expected. Adverse effects to possible chemical impurities are at least a theoretical consideration.<sup><xref ref-type="bibr" rid="bibr15-1078155211436023">15</xref></sup> The probability of an allergic reaction in our patient was estimated by an overall score of 9 on Naranjo nomogram for adverse drug reaction assessment. A score in this range defines an allergic reaction as ‘definite’. However, the exact mechanism is not known and represents a matter of debate. T-cell-mediated hypersensitivity to various drugs, including fluorinated quinolones, has been described in the literature.<sup><xref ref-type="bibr" rid="bibr6-1078155211436023">6</xref>,16</sup> Non-immune, idiopathic urticariform reactions, mediated by complement system and other plasmatic systems are also possible. Apart from the borderline elevated eosinophils compared to baseline values, no other distinct laboratory abnormalities suggestive of an allergic reaction were found in our patients.</p>
<p>In conclusion, along with the expanding of the FDG-PET/CT imaging, allergic reactions to F18-FDG may occur. Although rare, they must be made widely known to insure early diagnosis and potentially fatal outcomes. Although there are no established treatment recommendations for the FDG-induced allergies, it would not be unreasonable to follow standard protocols for the management of allergic reactions. We advocate secondary prophylactic measures, such as premedication with steroids and H<sub>1</sub>-receptor blockers, for patients with known allergies to the F18-FDG before exposing them again to these agents.</p>
</sec>
</body>
<back>
<sec id="sec4-1078155211436023"><title>Funding</title>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</sec>
<sec id="sec5-1078155211436023"><title>Competing interests</title>
<p>The authors declare that they have no competing interests.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="bibr1-1078155211436023"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Epstein</surname><given-names>E</given-names></name></person-group>. <article-title>Letter: fluoride toothpastes as a cause of acne-like eruptions</article-title>. <source>Arch Dermatol</source> <year>1976</year>; <volume>112</volume>(<issue>7</issue>): <fpage>1033</fpage>–<lpage>1034</lpage>.</citation></ref>
<ref id="bibr2-1078155211436023"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Keanie</surname><given-names>H</given-names></name></person-group>. <article-title>Fluoride allergy</article-title>. <source>Br Dent J</source> <year>2007</year>; <volume>202</volume>(<issue>9</issue>): <fpage>507</fpage>–<lpage>508</lpage>.</citation></ref>
<ref id="bibr3-1078155211436023"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vellore</surname><given-names>AD</given-names></name><name><surname>Drought</surname><given-names>VJ</given-names></name><name><surname>Sherwood-Jones</surname><given-names>D</given-names></name><name><surname>Tunnicliffe</surname><given-names>B</given-names></name><name><surname>Moore</surname><given-names>VC</given-names></name><name><surname>Robertson</surname><given-names>AS</given-names></name><etal/></person-group>. <article-title>Occupational asthma and allergy to sevoflurane and isoflurane in anaesthetic staff</article-title>. <source>Allergy</source> <year>2006</year>; <volume>61</volume>(<issue>12</issue>): <fpage>1485</fpage>–<lpage>1486</lpage>.</citation></ref>
<ref id="bibr4-1078155211436023"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Finch</surname><given-names>TM</given-names></name><name><surname>Muncaster</surname><given-names>A</given-names></name><name><surname>Prais</surname><given-names>L</given-names></name><name><surname>Foulds</surname><given-names>IS</given-names></name></person-group>. <article-title>Occupational airborne allergic contact dermatitis from isoflurane vapour</article-title>. <source>Contact Dermat</source> <year>2000</year>; <volume>42</volume>(<issue>1</issue>): <fpage>46</fpage>–<lpage>46</lpage>.</citation></ref>
<ref id="bibr5-1078155211436023"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Scherer</surname><given-names>K</given-names></name><name><surname>Bircher</surname><given-names>AJ</given-names></name></person-group>. <article-title>Hypersensitivity reactions to fluoroquinolones</article-title>. <source>Curr Allergy Asthma Rep</source> <year>2005</year>; <volume>5</volume>(<issue>1</issue>): <fpage>15</fpage>–<lpage>21</lpage>.</citation></ref>
<ref id="bibr6-1078155211436023"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schmid</surname><given-names>DA</given-names></name><name><surname>Depta</surname><given-names>JP</given-names></name><name><surname>Pichler</surname><given-names>WJ</given-names></name></person-group>. <article-title>T cell-mediated hypersensitivity to quinolones: mechanisms and cross-reactivity</article-title>. <source>Clin Exp Allergy</source> <year>2006</year>; <volume>36</volume>(<issue>1</issue>): <fpage>59</fpage>–<lpage>69</lpage>.</citation></ref>
<ref id="bibr7-1078155211436023"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fabre</surname><given-names>B</given-names></name><name><surname>Albes</surname><given-names>B</given-names></name><name><surname>Belhadjali</surname><given-names>H</given-names></name><name><surname>Bazex</surname><given-names>J</given-names></name></person-group>. <article-title>Acute generalized exanthematous pustulosis due to fluconazole</article-title>. <source>Ann Dermatol Venereol</source> <year>2002</year>; <volume>129</volume>(<issue>3</issue>): <fpage>294</fpage>–<lpage>297</lpage>.</citation></ref>
<ref id="bibr8-1078155211436023"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Heikkila</surname><given-names>H</given-names></name><name><surname>Timonen</surname><given-names>K</given-names></name><name><surname>Stubb</surname><given-names>S</given-names></name></person-group>. <article-title>Fixed drug eruption due to fluconazole</article-title>. <source>J Am Acad Dermatol</source> <year>2000</year>; <volume>42</volume>(<issue>5 Pt 2</issue>): <fpage>883</fpage>–<lpage>884</lpage>.</citation></ref>
<ref id="bibr9-1078155211436023"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lester</surname><given-names>LJ</given-names></name><name><surname>Brantley</surname><given-names>JS</given-names></name><name><surname>Kelso</surname><given-names>RL</given-names></name><name><surname>Kelly</surname><given-names>BC</given-names></name><name><surname>Petitt</surname><given-names>MS</given-names></name><name><surname>Wilkerson</surname><given-names>MG</given-names></name></person-group>. <article-title>Severe cutaneous adverse drug reaction due to fluconazole</article-title>. <source>J Drugs Dermatol</source> <year>2008</year>; <volume>7</volume>(<issue>11</issue>): <fpage>1084</fpage>–<lpage>1087</lpage>.</citation></ref>
<ref id="bibr10-1078155211436023"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Malik</surname><given-names>R</given-names></name><name><surname>Medeiros</surname><given-names>C</given-names></name><name><surname>Wigney</surname><given-names>DI</given-names></name><name><surname>Love</surname><given-names>DN</given-names></name></person-group>. <article-title>Suspected drug eruption in seven dogs during administration of flucytosine</article-title>. <source>Aust Vet J</source> <year>1996</year>; <volume>74</volume>(<issue>4</issue>): <fpage>285</fpage>–<lpage>288</lpage>.</citation></ref>
<ref id="bibr11-1078155211436023"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Richard</surname><given-names>MA</given-names></name><name><surname>Fiszenson</surname><given-names>F</given-names></name><name><surname>Jreissati</surname><given-names>M</given-names></name><name><surname>Jean Pastor</surname><given-names>MJ</given-names></name><name><surname>Grob</surname><given-names>JJ</given-names></name></person-group>. <article-title>Cutaneous adverse effects during selective serotonin reuptake inhibitors therapy: 2 cases</article-title>. <source>Ann Dermatol Venereol</source> <year>2001</year>; <volume>128</volume>(<issue>6–7</issue>): <fpage>759</fpage>–<lpage>761</lpage>.</citation></ref>
<ref id="bibr12-1078155211436023"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Figueredo</surname><given-names>E</given-names></name><name><surname>Cuesta-Herranz</surname><given-names>JI</given-names></name><name><surname>De Las Heras</surname><given-names>M</given-names></name><name><surname>Lluch-Bernal</surname><given-names>M</given-names></name><name><surname>Umpierrez</surname><given-names>A</given-names></name><name><surname>Sastre</surname><given-names>J</given-names></name></person-group>. <article-title>Anaphylaxis to dexamethasone</article-title>. <source>Allergy</source> <year>1997</year>; <volume>52</volume>(<issue>8</issue>): <fpage>877</fpage>–<lpage>877</lpage>.</citation></ref>
<ref id="bibr13-1078155211436023"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Karsh</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>WH</given-names></name></person-group>. <article-title>An anaphylactic reaction to intra-articular triamcinolone: a case report and review of the literature</article-title>. <source>Ann Allergy Asthma Immunol</source> <year>2003</year>; <volume>90</volume>(<issue>2</issue>): <fpage>254</fpage>–<lpage>258</lpage>.</citation></ref>
<ref id="bibr14-1078155211436023"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sener</surname><given-names>O</given-names></name><name><surname>Caliskaner</surname><given-names>Z</given-names></name><name><surname>Yazicioglu</surname><given-names>K</given-names></name><name><surname>Karaayvaz</surname><given-names>M</given-names></name><name><surname>Ozanguc</surname><given-names>N</given-names></name></person-group>. <article-title>Nonpigmenting solitary fixed drug eruption after skin testing and intra-articular injection of triamcinolone acetonide</article-title>. <source>Ann Allergy Asthma Immunol</source> <year>2001</year>; <volume>86</volume>(<issue>3</issue>): <fpage>335</fpage>–<lpage>336</lpage>.</citation></ref>
<ref id="bibr15-1078155211436023"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kuge</surname><given-names>Y</given-names></name><name><surname>Nishijima</surname><given-names>K</given-names></name><name><surname>Nagatsu</surname><given-names>K</given-names></name><name><surname>Seki</surname><given-names>K</given-names></name><name><surname>Ohkura</surname><given-names>K</given-names></name><name><surname>Tanaka</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Chemical impurities in [18F]FDG preparations produced by solid-phase 18F-fluorination</article-title>. <source>Nucl Med Biol</source> <year>2002</year>; <volume>29</volume>(<issue>2</issue>): <fpage>275</fpage>–<lpage>279</lpage>.</citation></ref>
<ref id="bibr16-1078155211436023"><label>16</label><citation citation-type="other"><comment>Schnyder B and Pichler WJ. Mechanisms of drug-induced allergy. <italic>Mayo Clin Proc</italic> 2009; 84(3): 268–272</comment>.</citation></ref>
</ref-list>
</back>
</article>